CCH Holdings prices IPO at $4 per share on NASDAQ
LONDON - Investment firm M&G Plc has increased its stake in Ondine Biomedical Inc to 12.97% from 9.18%, according to a regulatory filing released Thursday.
The transaction, which involved the placement of shares, was executed on September 3, with the notification to the issuer made on September 4, as detailed in the standard form for notification of major holdings.
Following the transaction, M&G now holds 67,254,901 voting rights in the Canada-based biomedical company. The stake is held through a chain of controlled undertakings, starting with M&G Plc as the parent company and flowing through several wholly owned subsidiaries, including M&G Group Regulated Entity Holding Company Limited, M&G Group Limited, M&G FA Limited, and ultimately M&G Investment Management Limited.
The notification indicates that M&G’s position consists entirely of voting rights attached to shares, with no additional voting rights through financial instruments.
Ondine Biomedical Inc is listed with the international securities identification number (ISIN) CA68234M2058.
The information was disclosed in a regulatory filing based on a press release statement published through the London Stock Exchange’s news service.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.